INMED PHARMACEUTICALS INC. Deferred Tax Assets, Capital Loss Carryforwards
INMED PHARMACEUTICALS INC. (INM) had Deferred Tax Assets, Capital Loss Carryforwards of $29.21 million as of 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2026-09-09
- 2026-06-30: Deferred Tax Assets, Capital Loss Carryforwards $29.21M.
- 2025-06-30: Deferred Tax Assets, Capital Loss Carryforwards $25.46M.
- 2024-06-30: Deferred Tax Assets, Capital Loss Carryforwards $21.50M.
- 2023-06-30: Deferred Tax Assets, Capital Loss Carryforwards $19.49M.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2026-06-30 | $29.21M S-4/A · filed 2026-09-09 |
| 2025-06-30 | $25.46M S-4/A · filed 2026-09-09 |
| 2024-06-30 | $21.50M S-4 · filed 2026-07-02 |
| 2023-06-30 | $19.49M 10-K · filed 2024-09-30 |
| 2022-06-30 | $17.00M 10-K · filed 2023-09-29 |
| 2021-06-30 | $13.74M 10-K · filed 2022-09-23 |
| 2020-06-30 | $9.84M 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |